TCF-19 CRISPR/Cas9 KO Plasmid (h): sc-404549
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- TCF-19 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the TCF-19 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: TCF-19 Antibody (H-2): sc-390923
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TCF-19 CRISPR/Cas9 KO Plasmid (h) | sc-404549 | 20 µg | $397.00 |
Overview
TCF19 (transcription factor 19) encodes TCF-19, a nuclear DNA-binding protein enriched in proliferative cells and linked to transcriptional control programs that coordinate cell-cycle progression. It has been associated with regulation of genes involved in DNA replication and S-phase entry, supporting pathways that couple chromatin dynamics with growth signals. Altered TCF19 expression has been reported across multiple tumor contexts and is also implicated by genetic and functional studies in immune and metabolic phenotypes, including autoimmune susceptibility. These connections make TCF-19 a useful target for dissecting transcriptional networks that influence proliferation, genome maintenance, and inflammatory signaling.
TCF-19 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the TCF19 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the TCF19 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the TCF19 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish TCF-19 protein expression.
This CRISPR knockout system enables efficient generation of TCF19-deficient cell models for investigation of TCF-19 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting TCF19 exon(s) critical for TCF-19 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple TCF19 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by TCF-19 CRISPR/Cas9 KO Plasmid (h) and TCF-19 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the TCF19 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by TCF-19 HDR Plasmid (h) and TCF-19 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by TCF19 homology arms to support homology-directed repair at defined TCF19 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.